Fusion Pharmaceuticals Inc (Nasdaq: FUSN), a clinical-stage oncology company, announced on Tuesday that it has named Eric S Hoffman, PhD as its new senior vice president, business development.
Dr Hoffman has over 15 years' experience in the biotechnology industry. He has served as chief business officer at Vicarius Pharma, chief business officer of Genocea Biosciences, vice president of corporate and business development and executive director of investor relations and corporate communications at Idenix Pharmaceuticals.
Previously Dr Hoffman was director of corporate and business development and director of investor relations at Biogen Idec. He has also served for over five years on Wall Street as a biotechnology equity analyst at JPMorgan Securities and a biotechnology research associate at Bear Stearns International.
Dr Hoffman was a post-doctoral research associate in the Department of Immunobiology at King's College in London. He has a PhD in molecular, cellular and developmental biology with a focus on T cell immunology from Yale University, and a BS in biology from Trinity University.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886